1 BTC
=
- USD
DaVita Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Market Statistics
Trading Metrics
How to Buy DVA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy DVA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesU.S. equities hit fresh record highs on May 6, 2026, with the S&P 500 and Nasdaq 100 reaching all-time peaks. AMD and Super Micro Computer surged 16% on strong AI-driven earnings, while oil prices collapsed 6-7% on diplomatic hopes between Washington and Tehran. Technology stocks led gains, though energy stocks declined sharply. Mixed earnings results saw winners like Flex Ltd. (+30%) and DaVita (+18%), while CDW and Coupang fell 20% and 17.5% respectively.
The American Heart Association has introduced the Cardiovascular-Kidney-Metabolic (CKM) Health Initiative to increase awareness of the interconnected nature of heart disease, kidney disease, diabetes, and obesity. Nearly 90% of U.S. adults have at least one CKM risk factor, yet many cases remain undiagnosed. The initiative encourages regular screening and lifestyle modifications to prevent complications.
R1 Therapeutics, a new clinical-stage biopharmaceutical company, launched with an oversubscribed $77.5 million Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. The company licensed exclusive global rights (outside Greater China) to AP306 from Alebund Pharmaceuticals, a first-in-class pan phosphate transporter inhibitor for treating hyperphosphatemia in chronic kidney disease patients on dialysis. R1 plans to advance Phase 2b clinical development of AP306, addressing a significant unmet need affecting over 40% of US dialysis patients.
Following Warren Buffett's retirement and Greg Abel's appointment as CEO of Berkshire Hathaway, the article highlights three Warren Buffett stocks with solid long-term potential: Chevron, benefiting from rising oil prices and operational improvements; Domino's Pizza, outperforming competitors with positive same-store sales growth and potential for higher valuation; and DaVita, showing signs of quiet recovery with strong Q4 results and promising 2026 guidance despite past struggles.
The article analyzes three Warren Buffett holdings: American Express is recommended as a buy despite a 20% pullback due to its strong position with affluent borrowers; Constellation Brands is suggested as a buying opportunity despite current weakness, as the beer industry is cyclical and the company is undergoing strategic improvements; DaVita is flagged as a stock to avoid due to deteriorating healthcare industry fundamentals and Berkshire's recent exit from the position.
